export const PressRelease = [
  {
    year: 2022,
    date: "May 26, 2022",
    title:
      "FDA Approves RADICAVA ORS® (edaravone) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS) by Mitsubishi Tanabe",
    summarry:
      "Brand Institute is proud to announce working with Mitsubishi Tanabe in developing the brand name Radicava ORS®, approved by the Food and Drug Administration (FDA) on May 12, 2022. FDA approved Radicava ORS (edaravone) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS).",
  },
  {
    year: 2022,
    date: "May 23, 2022",
    title:
      "Fujifilm's FIPAS™ Service Offers High-Tech Solution for Infrastructure Maintenance",
    summarry:
      "Brand Institute is proud to announce having worked with Fujifilm Corporation in developing the FIPAS™ brand name. FIPAS™ is a photo analysis service that utilizes cloud-based software to automatically identify deteriorations in concrete from photos and estimate their size.",
  },
  {
    year: 2022,
    date: "May 19, 2022",
    title: "Hyundai Updates Award Winning Venue® SUV for 2022",
    summarry:
      "Brand Institute is proud to announce having worked with Hyundai Motor Company in developing the brand name Venue®. Hyundai's Venue® recently received a 5-Year Cost to Own recognition award from Kelley Blue Book for a third consecutive year.",
  },
  {
    year: 2022,
    date: "May 04, 2022",
    title:
      "FDA Approves Orphalan's CUVRIOR™ (trientine tetrahydrochloride), the first treatment for Wilson's disease in over five decades",
    summarry:
      "Brand Institute is proud to announce working with rare disease specialist, Orphalan, in developing the brand name CUVRIOR™, approved by the United States Food and Drug Administration on April 28, 2022.",
  },
  {
    year: 2022,
    date: "Apr 18, 2022",
    title:
      "FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience",
    summarry:
      "Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed.",
  },
  {
    year: 2022,
    date: "Apr 25, 2022",
    title:
      "FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., developed by Lipocine Inc.",
    summarry:
      "Brand Institute is proud to announce working with Lipocine Inc. in developing the brand name TLANDO®, approved by the Food and Drug Administration (FDA) on March 28, 2022.",
  },
  {
    year: 2021,
    date: "Dec 22, 2021 ",
    title:
      "FDA Approves TEZSPIRE™ (tezepelumab-ekko), AstraZeneca and Amgen's First-in-Class Treatment for Severe Asthma",
    summarry:
      "Brand Institute is proud to announce its successful partnership with AstraZeneca and Amgen in naming TEZSPIRE™, the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients.",
  },
  {
    year: 2021,
    date: "Dec 21, 2021",
    title: "EMA Approves NUVAXOVID®, Novavax's COVID-19 Vaccine",
    summarry:
      "Brand Institute is proud to announce its successful partnership with Novavax in naming their EMA-approved COVID-19 vaccine: NUVAXOVID®.",
  },
  {
    year: 2021,
    date: "Dec 19, 2021",
    title:
      "Japan's MHLW Approves Booster Shot for SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine",
    summarry:
      "Brand Institute is proud to announce its successful partnership with Moderna in naming their mRNA COVID-19 vaccine: SPIKEVAX®.",
  },
  {
    year: 2021,
    date: "Dec 13, 2021",
    title:
      "FDA Approves Allergan's VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First Eye Drop Approved to Treat Age-Related Presbyopia in Adults",
    summarry:
      "Brand Institute is proud to announce its successful partnership with Allergan, Inc., an AbbVie company, in naming VUITY™, the first and only treatment approved by the U.S. Food & Drug Administration (FDA) to treat age-related blurry near vision (Presbyopia).",
  },
  {
    year: 2020,
    date: "Dec 28, 2020",
    title:
      "Introducing COMIRNATY®, the EU Brand Name forPfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute",
    summarry:
      "Brand Institute, the global leader in pharmaceutical and healthcare related name development, is proud to announce its role in naming Pfizer and BioNTech's COVID-19 vaccine: COMIRNATY® (koe mir' na tee).",
  },
];
